ENTA

Enanta is a pre-profit, chemistry-driven biotech whose only revenue is a declining HCV royalty stream from AbbVie's MAVYRET/MAVIRET. Revenue has fallen every year since FY2021 ($97.1M → $65.3M, -3.4% in FY2025) as the franchise matures, and the company runs deep operating losses: FY2025 operating income of -$85.3M on $65.3M of revenue (-130.7% operating margin) and a -$81.9M net loss. Returns are structurally negative (ROE -126.5%) and accumulated deficit sits at -$405M. This is not a business you underwrite on earnings — the P/S of 6.7x is meaningless against a shrinking royalty; the entire equity value rests on unproven pipeline assets.

The balance sheet is the reason this is a hold and not an avoid. The 10-K states $188.9M in cash and short-term marketable securities at 9/30/25, plus October 2025 offering proceeds and retained MAVYRET royalties, funding operations into fiscal 2029 — a genuine multi-year runway. Current assets of $204M cover current liabilities of $48.6M ~4.2x, and operating cash burn actually improved 75.5% YoY to -$19.3M. The cost of that survival is dilution: shares outstanding jumped 36.2% YoY, and the $436M market cap already embeds roughly $189M of cash, leaving ~$247M of enterprise value for the pipeline.